Cart
sales@molnova.com
GSK-3008348
CAS No. 1629249-33-7
GSK-3008348( GSK3008348 )
Catalog No. M12439 CAS No. 1629249-33-7
GSK-3008348 is a novel potent, selective integrin αvβ6 antagonist for the treatment of idiopathic pulmonary fibrosis (IPF).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 1430 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK-3008348
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK-3008348 is a novel potent, selective integrin αvβ6 antagonist for the treatment of idiopathic pulmonary fibrosis (IPF).
-
DescriptionGSK-3008348 is a novel potent, selective integrin αvβ6 antagonist for the treatment of idiopathic pulmonary fibrosis (IPF).Cystic Fibrosis Phase 1 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsGSK3008348
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorIntegrin
-
Research AreaOther Indications
-
IndicationFibrosis
Chemical Information
-
CAS Number1629249-33-7
-
Formula Weight487.636
-
Molecular FormulaC29H37N5O2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(O)C[C@@H](C1=CC=CC(N2N=C(C)C=C2C)=C1)CN3C[C@@H](CCC4=NC5=C(CCCN5)C=C4)CC3
-
Chemical Name(3S)-3-[3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl]-4-{(3S)-3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-1-pyrrolidinyl}butanoic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
α2β1 integrin-IN-15
α2β1 integrin-IN-15 highly potent, selective, allosteric small-molecule inhibitor of integrin α2β1 with IC50 of 12 nM.
-
Roxifiban acetate
Roxifiban acetate（DMP 754 acetate） is a potent GP IIb / IIIa antagonist that exhibits antiplatelet aggregation activity via immune mediation and can be used in the study of human thrombocytopenia.
-
ATN-161 trifluoroace...
ATN-161 trifluoroacetate salt is a novel integrin α5β1 antagonist that inhibits angiogenesis and growth of liver metastases in a murine model.The combination of ATN-161 plus 5-FU significantly reduces tumor cell proliferation compared to control and single-agent therapy.
